Category Archives: Jim’s Corner

First Person: An Advocate for Healthcare Innovations Becomes a Patient

Patients are always on our minds at BIO as we work to increase access to safe and effective therapies by advancing policies that support innovation. We all have friends and family members living with chronic conditions or fighting life-threatening diseases, such as cancer, Parkinson’s or ALS. Disease hit close to home recently when a member of the BIO family, Deputy General Counsel for Healthcare Sandi Dennis, was diagnosed with breast cancer. Fortunately, it was caught Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Therapeutic Discovery Program Is a Shot in the Arm for Small Biotechs

Innovation is one of the things Americans do best and when it comes to creating new therapies, it’s also a key to job growth, strong small businesses, and our industry’s ability to address the needs of patients suffering from debilitating diseases such as cancer, HIV/AIDS and Alzheimer’s. The recently implemented Therapeutic Discovery Project Program offers a tax credit to small biotechnology companies on the cusp of discovering cutting-edge treatments and technologies that will have a Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Misguided Fear of Biotech Should Not Translate to Regulatory Hurdles

A recent editorial in the New York Times lays bare how demonization of biotechnology hinders innovations that can “save lives and protect the environment.” Opponents of genetic engineering stoke consumer distrust of biotechnology, against all evidence of the industry’s safety record, only to drive up regulatory costs for biotech companies, argue the authors, Pamela C. Ronald, a professor of plant pathology at the University of California, Davis, and co-author of Tomorrow’s Table, and James E. Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

Maintaining a Healthy Biotech Industry

For emerging biotech companies, the economic climate remains challenging. As of April 2010, 38 percent of public biotech companies were operating with less than a year of cash and 24 percent were operating with six months or less of cash, much higher than historic averages. Investors remain wary of taking risks, particularly given the current volatility in global financial markets, and biotech investments are a risky proposition. A biotech discovery runs a one in 5,000 Read More >

Jim's Corner  |  Leave a comment  |  Email This Post

BIO Media Briefing Provides Update on Key Public Policy Issues

BIO hosted a media briefing on Wednesday, June 30th, with Jim Greenwood and Rachel King, Co-Founder and CEO of GlycoMimetics, Inc. and member of BIO’s Executive Committee. Jim and Rachel addressed the public policies under consideration by Congress, regulatory agencies and the courts which have the potential to impact the biotechnology industry.  Key discussion topics included implementation of health care reform (biosimilars, comparative effectiveness, Therapeutic Discovery Project Program, and Cures Acceleration Network), upcoming reauthorization of Read More >

Jim's Corner  |  Leave a comment  |  Email This Post